Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amarin Corporation plc
Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis
July 3rd, 2009
Amarin Corporation plc (NASDAQ:AMRN) announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic autoimmune disease characterized by muscle weakness which can be life-threatening. Thomas Lynch, Chairman and Chief Executive Officer of Amarin, commented "We are pleased to announce this update regarding the EN101 program. EN101 is one of our CNS assets that we plan to partner as a consequence of the Company's recent focusing of development efforts on cardiovascular disease programs. We expect this data will be of interest to any future potential...
Source: Health Business Week (2009-07-03)
|
